Lead Product(s): CY6463
Therapeutic Area: Neurology Product Name: CY6463
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cyclerion Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
IXICO has been selected by Cyclerion Therapeutics, Inc., a new client, to support the company's Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer's disease.